Volume Alert - GILD 106.54 Gilead Sciences $GILD H
Post# of 162
Posted On: 11/12/2014 11:30:33 AM
Volume Alert - GILD 106.54 Gilead Sciences $GILD Hit a high today of 107.81 Closing the day 10:30 at 106.54 -1.47 -1.36% With a day low of 105.70 and a total volume of 3,398,247.
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - 12 mins ago
GILD: 106.85 (-1.16)
Early Glance: Biotechnology companies
AP - 24 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.01 (-0.84)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - 2 hrs 41 mins ago
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.01 (-1.48), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), DNDN: 0.16 (+0.01), AMGN: 161.31 (-1.11), ABBV: 63.84 (-0.01), REGN: 399.27 (+0.91)
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - 2 hrs 44 mins ago
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ
NDN), and Juniper (NYSE:JNPR).
GILD: 106.85 (-1.16), DNDN: 0.16 (+0.01), ZNGA: 2.82 (+0.07), AAPL: 110.62 (+0.92), JNPR: 20.54 (+0.26), BABA: 117.35 (+2.81)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 46 mins ago
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.10 (-0.56), SJR: 25.86 (-0.22), PRGO: 154.26 (-1.18), XYL: 37.33 (-0.02), CHRW: 72.10 (+0.35), MDLZ: 37.67 (-0.10), MKC: 72.79 (-0.43), MDU: 25.41 (-0.30), SYY: 38.81 (+0.29), PDCO: 44.63 (+0.36), PNR: 67.98 (-0.14), TRI: 38.10 (+0.18), UPS: 107.98 (-0.78), PEP: 96.91 (+0.21), AGN: 197.22 (+1.88), MSI: 63.64 (+0.09), NOV: 73.29 (+0.19), NWN: 46.87 (-0.62), EGN: 68.07 (-0.71), EBAY: 53.89 (-0.30), QCOM: 70.27 (+0.63), AMAT: 22.38 (-0.16), ACN: 83.74 (-0.20), AAPL: 110.62 (+0.92), MA: 84.14 (-0.45), SCHW: 28.73 (-0.12), STR: 23.78 (-0.51), SE: 39.03 (-0.30), GAS: 52.02 (-1.25), IRM: 37.99 (+0.16), WM: 49.35 (-0.01), CMP: 88.71 (+0.69), VRSK: 62.85 (-0.16), GILD: 106.85 (-1.16), EXPD: 44.03 (-0.23), TFX: 113.85 (-0.48), CVS: 89.19 (-0.57), PG: 89.63 (-0.04), PX: 126.08 (-0.62), NVS: 92.66 (-0.11)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.22 (+1.88), GILD: 106.85 (-1.16), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)
Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 106.85 (-1.16)
Final Glance: Biotechnology companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.56 (-0.35), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), AMAG: 34.74 (-0.14)
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 106.85 (-1.16), MRK: 59.20 (-0.17)
Gilead: Another Competitor Bites The Dust
Bret Jensen - at Seeking Alpha - Tue Nov 11, 1:10PM CST
GILD: 106.85 (-1.16)
Midday Glance: Biotechnology companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.84 (-1.17), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)
Conatus Pharmaceuticals (CNAT): Will Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 12:50PM CST
Conatus Pharmaceuticals Inc, Inc. (CNAT) is expected to report third-quarter 2014 results on Nov 12.
MNK: 93.22 (-0.49), GILD: 106.86 (-1.15), CNAT: 6.87 (-0.19), ICPT: 155.82 (-17.31)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 116.01 (-1.48), GILD: 106.86 (-1.15), MRK: 59.20 (-0.17), DNDN: 0.16 (+0.01), AZN: 74.13 (-0.07), TEVA: 58.20 (+0.01), ABBV: 63.85 (unch), GSK: 45.65 (-0.31), BMY: 58.55 (-0.17), NVS: 92.66 (-0.11)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 377.95 (-4.60), YHOO: 49.96 (+0.91), AMZN: 309.71 (-2.30), BIIB: 319.95 (-4.64), VRTX: 116.01 (-1.48), FEYE: 32.64 (-0.21), LNKD: 229.43 (-1.57), EBAY: 53.89 (-0.30), GILD: 106.86 (-1.15), AMGN: 161.31 (-1.11), ABBV: 63.85 (unch), REGN: 399.27 (+0.91), CELG: 107.02 (-0.83)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - 12 mins ago
GILD: 106.85 (-1.16)
Early Glance: Biotechnology companies
AP - 24 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.01 (-0.84)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - 2 hrs 41 mins ago
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.01 (-1.48), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), DNDN: 0.16 (+0.01), AMGN: 161.31 (-1.11), ABBV: 63.84 (-0.01), REGN: 399.27 (+0.91)
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - 2 hrs 44 mins ago
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ
NDN), and Juniper (NYSE:JNPR). GILD: 106.85 (-1.16), DNDN: 0.16 (+0.01), ZNGA: 2.82 (+0.07), AAPL: 110.62 (+0.92), JNPR: 20.54 (+0.26), BABA: 117.35 (+2.81)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 46 mins ago
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.10 (-0.56), SJR: 25.86 (-0.22), PRGO: 154.26 (-1.18), XYL: 37.33 (-0.02), CHRW: 72.10 (+0.35), MDLZ: 37.67 (-0.10), MKC: 72.79 (-0.43), MDU: 25.41 (-0.30), SYY: 38.81 (+0.29), PDCO: 44.63 (+0.36), PNR: 67.98 (-0.14), TRI: 38.10 (+0.18), UPS: 107.98 (-0.78), PEP: 96.91 (+0.21), AGN: 197.22 (+1.88), MSI: 63.64 (+0.09), NOV: 73.29 (+0.19), NWN: 46.87 (-0.62), EGN: 68.07 (-0.71), EBAY: 53.89 (-0.30), QCOM: 70.27 (+0.63), AMAT: 22.38 (-0.16), ACN: 83.74 (-0.20), AAPL: 110.62 (+0.92), MA: 84.14 (-0.45), SCHW: 28.73 (-0.12), STR: 23.78 (-0.51), SE: 39.03 (-0.30), GAS: 52.02 (-1.25), IRM: 37.99 (+0.16), WM: 49.35 (-0.01), CMP: 88.71 (+0.69), VRSK: 62.85 (-0.16), GILD: 106.85 (-1.16), EXPD: 44.03 (-0.23), TFX: 113.85 (-0.48), CVS: 89.19 (-0.57), PG: 89.63 (-0.04), PX: 126.08 (-0.62), NVS: 92.66 (-0.11)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.22 (+1.88), GILD: 106.85 (-1.16), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)
Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 106.85 (-1.16)
Final Glance: Biotechnology companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.56 (-0.35), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), AMAG: 34.74 (-0.14)
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 106.85 (-1.16), MRK: 59.20 (-0.17)
Gilead: Another Competitor Bites The Dust
Bret Jensen - at Seeking Alpha - Tue Nov 11, 1:10PM CST
GILD: 106.85 (-1.16)
Midday Glance: Biotechnology companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.84 (-1.17), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)
Conatus Pharmaceuticals (CNAT): Will Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 12:50PM CST
Conatus Pharmaceuticals Inc, Inc. (CNAT) is expected to report third-quarter 2014 results on Nov 12.
MNK: 93.22 (-0.49), GILD: 106.86 (-1.15), CNAT: 6.87 (-0.19), ICPT: 155.82 (-17.31)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 116.01 (-1.48), GILD: 106.86 (-1.15), MRK: 59.20 (-0.17), DNDN: 0.16 (+0.01), AZN: 74.13 (-0.07), TEVA: 58.20 (+0.01), ABBV: 63.85 (unch), GSK: 45.65 (-0.31), BMY: 58.55 (-0.17), NVS: 92.66 (-0.11)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 377.95 (-4.60), YHOO: 49.96 (+0.91), AMZN: 309.71 (-2.30), BIIB: 319.95 (-4.64), VRTX: 116.01 (-1.48), FEYE: 32.64 (-0.21), LNKD: 229.43 (-1.57), EBAY: 53.89 (-0.30), GILD: 106.86 (-1.15), AMGN: 161.31 (-1.11), ABBV: 63.85 (unch), REGN: 399.27 (+0.91), CELG: 107.02 (-0.83)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)
(0)
(0)Gilead Sciences Inc. (GILD) Stock Research Links
Scroll down for more posts ▼